Study Overview: This study is for adults with asthma to test a new treatment called solriktug. The study is in Phase 2, which means it's early in testing to see if the treatment is safe and how the body reacts to it. Solriktug is given as an injection under the skin. A placebo, which looks like the treatment but has no medicine, is used for comparison. The study lasts 12 weeks, with an extra 16 weeks for follow-up.
- Duration: The main treatment period is 12 weeks, plus a 16-week follow-up.
- Visits: Participants will visit the study site for injections.
- Eligibility: Adults aged 18-75 with asthma for at least 12 months.
Key Considerations: You cannot join if you are pregnant, a smoker, or have other serious health issues. Participants will be closely monitored throughout the study. This is important to ensure your safety and gather accurate data on solriktug.
How understandable was the trial content above?
Hard to understand
Easy to understand